APA (7th ed.) Citation

Mavratzas, A., Baek, S., Schneeweiss, A., & Marmé, F. (2019). Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. The breast, 45, . https://doi.org/10.1016/j.breast.2019.02.002

Chicago Style (17th ed.) Citation

Mavratzas, Athanasios, Sunhwa Baek, Andreas Schneeweiss, and Frederik Marmé. "Sorafenib in Combination with Docetaxel as First-line Therapy for HER2-negative Metastatic Breast Cancer: Final Results of the Randomized, Double-blind, Placebo-controlled Phase II MADONNA Study." The Breast 45 (2019). https://doi.org/10.1016/j.breast.2019.02.002.

MLA (9th ed.) Citation

Mavratzas, Athanasios, et al. "Sorafenib in Combination with Docetaxel as First-line Therapy for HER2-negative Metastatic Breast Cancer: Final Results of the Randomized, Double-blind, Placebo-controlled Phase II MADONNA Study." The Breast, vol. 45, 2019, https://doi.org/10.1016/j.breast.2019.02.002.